ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure
NCT ID: NCT00283361
Last Updated: 2007-02-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
130 participants
INTERVENTIONAL
2006-01-31
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ZP120
I.v. catherization
6-minutes walk performance
Dyspnea severity assessment
Blood sampling for laboratory tests
ECG
Physical examination
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. A diagnosis of acute or subacute decompensated chronic heart failure, either ischemic or nonischemic, requiring hospitalization, and currently treated with furosemide, torsemide, or bumetadine, and other evidence based optimal treatment for heart failure. Patients must have the clinical diagnosis of CHF made at least 3 month prior to enrollment
3. Ambulatory
4. Objective signs of LVD corresponding to a LVEF \< 45%, documented by any accepted method within the previous 12 months. If documentation is not available within the required time frame, LVEF must be assessed prior to enrollment
5. a) Worsening heart failure symptoms (current NYHA class III-IV). Patients must experience worsening of at least one of the symptoms described below at the time of entry into the study:
Dyspnea Symptoms:
* Dyspnea (labored or difficult breathing) at rest
* Worsening dyspnea (labored or difficult breathing) on minimal exertion
* Worsening orthopnea (difficult breathing except in the upright position)
* Increased frequency of nocturnal dyspnea (awaken from sleep due to respiratory distress)
b) Clinical evidence of volume overload such as weight gain over previous few days, peripheral edema, hepatic congestion with ascites, pulmonary congestion, or pleural effusion
6. Females of childbearing potential must have a negative pregnancy test at enrollment. A female is considered to be of childbearing potential unless she is post-menopausal (no menses for at least 12 consecutive months) or without a uterus and/or both ovaries
7. Ability to understand and willing to sign Informed Consent Form
Exclusion Criteria
2. Valvular heart disease requiring surgical intervention (during the course of the study. Patients with heart failure due to or associated with uncorrected primary valvular disease, malfunctioning artificial heart valve, or uncorrected congenital heart disease)
3. History of or clinically significant evidence of any severe disease other than heart failure that preclude participation and complicate the evaluation of study results from the local laboratory:
* Hepatic disease (AST, ALT, total bilirubin \> 3 times Upper Limit of Normal (ULN), renal disease (S-Creatinine \> 2.5 mg/dL),
* Uncontrolled insulin-dependent diabetes mellitus with a history of frequent hypoglycemic episodes or frequent hospitalizations for hyperglycemia,
* Cancer (excluding treated non-melanoma skin cancer)
4. Unstable angina, cardiogenic shock, or acute pulmonary edema requiring any of the following: Nitroprusside, intravenous nitroglycerin, nesiritide, intravenous inotrope, or need for endotracheal intubation and mechanical ventilation
5. Acute myocardial infarction and/or myocardial infarction within 30 days (prior to enrollment) as diagnosed by investigator's evaluation of clinical symptoms, ECG, and/or biochemical markers of cardiac injury
6. Cardiac arrest (patients with history of cardiac arrest within 12 months unless precipitated by an event such as an acute myocardial infarction, induction by catheter placement, severe transient electrolyte abnormality, by an electrophysiology procedure, or addressed by Automatic Implantable Cardioverter Defibrillator placement. Patients with increased risk of cardiac arrest, QTc \> 450 msec, atrial ventricular block II or III, etc.)
7. Sustainable VT/VF within 30 days (\> 15 seconds long; patients with enrollment ECG showing ventricular tachycardia or premature ventricular complexes associated with symptoms, or ventricular tachycardia of 6 beats)
8. Uncontrolled atrial fibrillation on enrollment ECG with a ventricular rate \>120 bpm
9. Cardiac surgery within the last month or acutely required PCI (patients who have undergone a cardiac revascularization, valvular surgery, or biventricular resynchronization procedure within 30 days. Patients who have had ventricular reduction surgery or cardiac myoplasty and patients with mechanical ventricular assist device)
10. Systolic blood pressure \< 90 mmHg and \> 200 mmHg
11. Pulmonary embolism or DVT or history of pulmonary embolism or DVT within 6 months prior to enrollment
12. Severe obstructive or restrictive pulmonary disease, patients with primary pulmonary hypertension and heart failure secondary to pulmonary disease, and severe pulmonary infection
13. I.v. vasoactive treatment, e.g. vasodilators, positive inotropic agents, within 24 hours prior to enrollment (see details in Appendix E)
14. Participation in another study evaluating an experimental treatment within the last 30 days which potentially could bias the outcome of this study
15. Previous treatment with ZP120
16. Patients known to abuse or actively abusing alcohol or illicit drugs. Abuse of alcohol is defined as the usual daily intake of more than 100 grams of ethanol per day, or more than approximately six 12-ounce bottles of beer, one 750 mL bottle of wine, or 250 mL of 80 proof spirits
17. Inability or unwillingness to provide informed consent
18. BMI outside range of 20-50 kg/m2 (BMI equal to 20 and 50 kg/m2 is accepted)
19. Any other condition or therapy, which in the opinion of the Principal Investigator would make the patient unsuitable for this study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Syneos Health
OTHER
Zealand Pharma
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
LAC-USC Medical Center-Division of Cardiology
Los Angeles, California, United States
VA Medical Center -WLA
Los Angeles, California, United States
UCSD Medical Center
San Diego, California, United States
San Francisco VA Medical Center
San Francisco, California, United States
University of CO Health Sciences Center
Denver, Colorado, United States
Health First Clinical Research Institute
Melbourne, Florida, United States
Univ. of Miami Miller School of Medicine, Jackson Memorial Medical Center
Miami, Florida, United States
Emory University Hospital/The Emory Clinic
Atlanta, Georgia, United States
Northside Hospital
Atlanta, Georgia, United States
Rush University Medical Center
Chicago, Illinois, United States
Community Hospital Anderson/Community Clinical Research Center
Anderson, Indiana, United States
University of Iowa Heart Failure Treatment Program
Iowa City, Iowa, United States
University of Maryland
Baltimore, Maryland, United States
Henry Ford Hospital
Detroit, Michigan, United States
Hennepin County Medical Center
Minneapolis, Minnesota, United States
The International Heart Institute
Missoula, Montana, United States
Bryan LGH Heart Institute
Lincoln, Nebraska, United States
University of Rochester Medical Center
Rochester, New York, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Lancaster Heart Foundation
Lancaster, Pennsylvania, United States
Albert Einstein Medical Center
Philadelphia, Pennsylvania, United States
Alamo Clinical Research Associates
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
05-025
Identifier Type: -
Identifier Source: org_study_id